In this episode of Peptalk, we're diving into Retatrutide. The groundbreaking triple-agonist peptide currently in Phase 3 trials. With the potential to outperform both Semaglutide (Wegovy) and Tirzepatide (Zepbound), this investigational drug targets GLP-1, GIP, and glucagon receptors for a powerful trifecta: appetite suppression, insulin sensitivity, and increased fat burn.
We break down the science behind Retatrutide, what makes it different, the impressive Phase 2 weight loss data (up to 24%!), and the risks like muscle loss you need to know about. If you're curious about the future of obesity treatment, metabolic health, or peptide therapies, this one's a must-listen.
Looking for guidance and professional help with your weight-loss journey, including being on these weightloss GLP-1's?
Contact us:
Andrea - andrea@rmhealthpartners.com
www.rmhealthpartners.com
Ashley- ashley@karvefitness.co
www.karvefitness.co
